Japannippon-shinyaku.co.jp/english
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto. It develops and markets prescription drugs, with a primary focus on hematology, oncology, and urology. The company collaborates on clinical development programs, such as the partnership with Chugai Pharmaceutical to expand the use of obinutuzumab (Gazyva) for idiopathic nephrotic syndrome in Japan.
Phase III INShore showed improved sustained remission and steroid reduction versus MMF; no new safety signals, supporting a regulatory application.
